Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Gene Therapy Increases Survival in Huntington's Disease Animal Models

By BiotechDaily International staff writers
Posted on 27 Jun 2013
Gene therapy that suppressed formation of glial cells while promoting growth of neurons in the adult brain slowed development of neurodegenerative Huntington's disease in animal models.

Huntington’s disease (HD) is caused by a dominant gene that encodes the huntingtin protein. The 5' end of the HD gene has a sequence of three DNA bases, cytosine-adenine-guanine (CAG), coding for the amino acid glutamine, that is repeated multiple times. Normal persons have a CAG repeat count of between 7 and 35 repeats, while the mutated form of the gene has anywhere from 36 to 180 repeats. The mutant form of huntingtin is broken down into toxic peptides, which cause the loss of a type of brain cell called striatopallidal medium spiny projection neurons (MSNs). Destruction of these cells causes involuntary movements, problems with coordination, and, ultimately, in cognitive decline and depression. There is currently no treatment for this fatal disease.

Investigators at the University of Rochester Medical Center (NY, USA) and their colleagues at the University of Iowa (Iowa City, USA) initially worked with a Huntington's disease mouse model. They injected these animals with adeno-associated viruses (AAVs) modified to deliver the genes for the proteins BDNF (brain derived neurotrophic factor) or noggin. BDNF stimulates neural stem cells to produce neurons, while noggin inhibits the molecular pathway that induces formation of glial cells.

Results reported in the June 6, 2013, issue of the journal Cell Stem Cell revealed that a single injection of the adeno-associated viruses AAV4-BDNF and AAV4-noggin triggered the sustained recruitment of new MSNs in wild-type and R6/2 mice, a Huntington's disease model. Mice treated with AAV4-BDNF/noggin or with BDNF and noggin proteins actively recruited progenitor cells to form new MSNs that matured and achieved circuit integration. The AAV4-BDNF/noggin-treated R6/2 mice showed delayed deterioration of motor function and substantially increased survival.

In a follow-up set of experiments, squirrel monkeys that were given injections of adenoviral BDNF/noggin showed similar addition of striatal neurons.

"This study demonstrates the feasibility of a completely new concept to treat Huntington's disease, by recruiting the brain's endogenous neural stem cells to regenerate cells lost to the disease," said senior author Dr. Steve Goldman, professor of neurology at the University of Rochester Medical Center. "The sustained delivery of BDNF and noggin into the adult brain was clearly associated with both increased neurogenesis and delayed disease progression. We believe that our data suggest the feasibility of this process as a viable therapeutic strategy for Huntington's disease."

Related Links:
University of Rochester Medical Center
University of Iowa



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.